Analysts expect that NanoString Technologies Inc (NASDAQ:NSTG) will announce ($0.58) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for NanoString Technologies’ earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.55). NanoString Technologies reported earnings per share of ($0.68) in the same quarter last year, which suggests a positive year-over-year growth rate of 14.7%. The company is scheduled to report its next earnings report on Thursday, March 5th.
On average, analysts expect that NanoString Technologies will report full year earnings of ($2.48) per share for the current financial year, with EPS estimates ranging from ($2.52) to ($2.45). For the next financial year, analysts anticipate that the company will post earnings of ($2.42) per share, with EPS estimates ranging from ($2.63) to ($2.03). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow NanoString Technologies.
NanoString Technologies (NASDAQ:NSTG) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). The firm had revenue of $30.60 million during the quarter, compared to analyst estimates of $28.05 million. NanoString Technologies had a negative net margin of 72.30% and a negative return on equity of 118.36%.
Several equities analysts have commented on NSTG shares. BidaskClub raised shares of NanoString Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, October 29th. ValuEngine raised shares of NanoString Technologies from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Finally, Zacks Investment Research lowered shares of NanoString Technologies from a “hold” rating to a “sell” rating in a report on Saturday.
In other news, SVP David W. Ghesquiere sold 18,421 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $28.23, for a total value of $520,024.83. Following the sale, the senior vice president now directly owns 52,572 shares in the company, valued at approximately $1,484,107.56. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Charles P. Waite, Jr. sold 1,707 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $21.75, for a total transaction of $37,127.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 86,253 shares of company stock worth $2,207,923. Insiders own 5.10% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of NanoString Technologies by 314.0% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,917,182 shares of the biotechnology company’s stock valued at $84,572,000 after purchasing an additional 2,970,963 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its stake in shares of NanoString Technologies by 56.9% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 3,904,451 shares of the biotechnology company’s stock valued at $84,297,000 after purchasing an additional 1,416,190 shares in the last quarter. ARK Investment Management LLC boosted its stake in shares of NanoString Technologies by 1.4% in the 2nd quarter. ARK Investment Management LLC now owns 3,526,095 shares of the biotechnology company’s stock valued at $107,017,000 after purchasing an additional 49,569 shares in the last quarter. BlackRock Inc. boosted its stake in shares of NanoString Technologies by 38.4% in the 2nd quarter. BlackRock Inc. now owns 3,094,485 shares of the biotechnology company’s stock valued at $93,918,000 after purchasing an additional 858,400 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of NanoString Technologies by 10.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,727,959 shares of the biotechnology company’s stock valued at $52,443,000 after purchasing an additional 166,877 shares in the last quarter.
NSTG stock traded down $0.63 during trading hours on Tuesday, reaching $23.12. The stock had a trading volume of 668,400 shares, compared to its average volume of 504,510. The company has a debt-to-equity ratio of 1.27, a current ratio of 5.21 and a quick ratio of 4.76. NanoString Technologies has a fifty-two week low of $13.26 and a fifty-two week high of $34.78. The stock has a market capitalization of $886.10 million, a PE ratio of -8.32 and a beta of 1.20. The stock has a 50-day simple moving average of $22.23 and a 200 day simple moving average of $25.86.
About NanoString Technologies
NanoString Technologies, Inc provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.
Featured Story: What is the Gross Domestic Product (GDP)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.